Key result
Pirfenidone increased survival and attenuated myocardial fibrosis and inflammatory mediators in a TAC-induced mouse model of left ventricular remodeling by inhibiting NLRP3 expression.
Why the study?
Does pirfenidone improve survival and attenuate myocardial fibrosis in a TAC-induced mouse model of hypertension and left ventricular hypertrophy?
Population
TAC-induced mouse model of hypertension and left ventricular hypertrophy
Design
Preclinical
Authors
Loading...
Should not change practice in hypertensive heart disease; leaves open translation of antifibrotic effects from animal models to humans.
Does pirfenidone improve survival and attenuate myocardial fibrosis in a TAC-induced mouse model of hypertension and left ventricular hypertrophy?
Pirfenidone attenuates cardiac fibrosis and improves survival in a mouse model of hypertension-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation.
Wang et al. (2013) studied Hypertension-induced left ventricular remodeling and myocardial fibrosis. Pirfenidone was evaluated on Survival, collagen deposition, heart function, and levels of fibrosis-related inflammatory cytokines and NLRP3. Pirfenidone increased survival and attenuated myocardial fibrosis and inflammatory mediators in a TAC-induced mouse model of left ventricular remodeling by inhibiting NLRP3 expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: